Close

Amicus Therapeutics (FOLD) Says Data From Phase 3 FACETS Study Published in NEJM

August 10, 2016 5:23 PM EDT Send to a Friend
Amicus Therapeutics (Nasdaq: FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that data from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login